Skip to main content

Table 3 Complications

From: Diabetes in Algeria and challenges for health policy: a literature review of prevalence, cost, management and outcomes of diabetes and its complications

Estimate

Study year

Sample frame and sample

Study design

Diagnostic test and diagnostic criteria

Reference

Diabetic retinopathy

2008

Sample frame: Three

Clinical screening

Diagnostic test: Blood samples

[13]

34.5% (N = 977, n = 300)

regions: Central, East, West

Diagnostic Criteria: ADA

DM1: 36.2% (n = 46)

 

Sample: 977 diabetes patients with DM1 (n = 136) and DM2 (n = 841)

  

DM2: 34.2% (n = 254)

 

Diabetic neuropathy

44.7% (N = 977, n = 433)

DM1: 35.8% (n = 48)

DM2: 46.2% (n = 385)

End-stage renal disease

.5% (N = 977, n = 5)

DM1: 0% (n = 0)

DM2: .6% (n = 5)

Diabetic retinopathy

Dec 2008-Jun 2009

Sample frame: Algiers province

Cross-sectional

Diagnostic test: N/A

[21]

DMT1/2: 48.6% ± 2.9%

Diagnostic Criteria: Alfediam criteria (Association de langue française pour l'étude du diabète et des maladies métaboliques)

Males: 49.6%

Females: 50.4%

Sample:

1,152 diabetes patients; 15 years of age or older with DM1, DM2 insulin-treated (IT) and DM2 non-insulin-treated (NIT) diabetes. Divided into three groups (n = 384) based on disease duration (less than 5 years, between 5–10 years, longer than 10 years).

DM1: 47.9% ± 7.0%

DM2 (IT and NIT.): 48.7% ± 5.2%

DMT2 (IT): 70.6% ±4.6%

DMT2 (NIT): 35.2% ± 3.8%

Proliferative diabetic retinopathy: 10.9% ± 1.8%